WaveMan
WaveMan · Company
AQST · Aquestive Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

AQST Aquestive Therapeutics (AQST) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001398733
Quote by TradingView
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
93
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $40.9K priced

What the filings say about AQST

Insiders, 180 days
-$744.0K net sold
3 sellers · 33% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$395.8K
3 notices

Aquestive Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Aquestive Therapeutics, Inc. insiders sold a net $744.0K of stock across 32 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Barber Daniel
President and CEO
SELL
2026-10-16 SECtraded 2026-10-15
25,000
$105.6K
+6.3%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (1 buy, 9 sales), the last on Sep 15, 2026.
  • The trade is 4.0% of the 627,317 shares held after it.
  • No other insider sold within 30 days.
  • 93 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Barber Daniel sold about $105.6K of AQST under a 10b5-1 plan on Oct 15, 2026; 93 funds added in the latest 13F quarter.
Barber Daniel
President and CEO
SELL
2026-09-16 SECtraded 2026-09-15
25,000
$120.5K
-12.7%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (1 buy, 8 sales), the last on Aug 17, 2026.
  • The trade is 3.8% of the 652,317 shares held after it.
  • 1 other insider sold within 30 days.
  • 93 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Barber Daniel sold about $120.5K of AQST under a 10b5-1 plan on Sep 15, 2026; 1 other insider sold within 30 days and 93 funds added in the latest 13F quarter.
Korczynski Sherry
Chief Commercial Officer
SELL
2026-09-11 SECtraded 2026-09-09
8,750
$45.7K
-16.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 10, 2026.
  • The trade is 3.7% of the 235,689 shares held after it.
  • 1 other insider sold within 30 days.
  • 93 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Korczynski Sherry sold about $45.7K of AQST under a 10b5-1 plan on Sep 9, 2026; 1 other insider sold within 30 days and 93 funds added in the latest 13F quarter.
Barber Daniel
President and CEO
SELL
2026-08-18 SECtraded 2026-08-17
25,000
$107.2K
-11.3%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (1 buy, 7 sales), the last on Jul 16, 2026.
  • The trade is 4.3% of the 585,574 shares held after it.
  • 1 other insider sold within 30 days.
  • 93 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Barber Daniel sold about $107.2K of AQST on Aug 17, 2026; 1 other insider sold within 30 days and 93 funds added in the latest 13F quarter.
Barber Daniel
President and CEO
SELL
2026-07-17 SECtraded 2026-07-16
20,369
$81.5K
+3.2%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (1 buy, 6 sales), the last on Jul 15, 2026.
  • The trade is 3.3% of the 610,574 shares held after it.
  • 1 other insider sold within 30 days.
  • 93 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Barber Daniel sold about $81.5K of AQST on Jul 16, 2026; 1 other insider sold within 30 days and 93 funds added in the latest 13F quarter.
32 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 27 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$744.0K over 180 days
-$378.9K over 90 days
below 60% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
93 funds bought in last quarter
more than 65% of Pharma & Biotech
Revenue
-22.6% year over year
below 70% of Pharma & Biotech
Margin
-188.1% net margin
below 64% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
24.4% of the float short (float per yahoo 2026-10-27) · 13.9 days to cover · settled 2026-10-15
more than 97% of Pharma & Biotech
What changed in the last 30 days
Oct 16President and CEO Barber Daniel sold $105.6K under a 10b5-1 plan (Oct 15)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.

Watch AQST

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-42.0%12M
-58%-39%-19%+0%2025-102025-122026-022026-042026-062026-082026-10 2026-03-10 · Barber Daniel sold $753.4K2026-03-10 · TOTH A ERNEST JR sold $242.9K2026-03-10 · Jung Cassie sold $190.9K2026-03-10 · BRAENDER LORI J sold $167.2K2026-06-23 · Krop Julie sold $125.5K2026-03-10 · Boyd Peter E. sold $124.3K2026-09-15 · Barber Daniel sold $120.5K2026-08-17 · Barber Daniel sold $107.2K2026-10-15 · Barber Daniel sold $105.6K2026-03-10 · Cioffi Melina sold $105.5K2026-06-15 · Barber Daniel sold $104.0K2026-07-16 · Barber Daniel sold $81.5K2026-03-10 · Korczynski Sherry sold $65.6K2026-09-09 · Korczynski Sherry sold $45.7K2026-05-15 · Barber Daniel sold $35.4K2026-07-15 · Barber Daniel sold $18.7K2026-09-15 · Daniel Barber filed to sell $244.0K2026-09-09 · Sherry M. Korczynski filed to sell $45.6K2026-08-17 · Daniel Barber filed to sell $106.2K2026-07-15 · Daniel Barber filed to sell $101.0K2026-06-23 · JULIE KROP filed to sell $118.0K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AQST: institutional holders (13F)

13F holdings, latest reported quarter
Bratton Capital Management, L.P.
9,810,958 sh
$40.8M
BlackRock, Inc.
8,069,373 sh
$33.6M
RTW INVESTMENTS, LP
7,426,471 sh
$30.9M
VANGUARD CAPITAL MANAGEMENT LLC
4,584,533 sh
$19.1M
FEDERATED HERMES, INC.
3,112,561 sh
$12.9M

Congress trades in AQST

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

AQST planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Daniel Barber
Filed 2026-09-15
$244.0K
Sherry M. Korczynski
Filed 2026-09-09
$45.6K
Daniel Barber
Filed 2026-08-17
$106.2K
Daniel Barber
Filed 2026-07-15
$101.0K
JULIE KROP
Filed 2026-06-23
$118.0K

AQST mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Propel Opportunities ETF
$1.2M position · as of 2026-06-30
1.5%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$3.3M position · as of 2026-06-30
0.8%
PROFUND VP PHARMACEUTICALS
$85.4K position · as of 2026-06-30
0.7%
Wasatch Ultra Growth Fund
$3.0M position · as of 2026-06-30
0.6%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$104.6K position · as of 2026-07-31
0.5%
Wasatch Micro Cap Fund
$2.7M position · as of 2026-06-30
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
1
Phase 2
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $744.0K sold by insiders over 180 days, 93 funds added last quarter, $395.8K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

AQST financials

Revenue growth
-22.6%
XBRL, annual
Net margin
-188.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$54.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-144.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$45.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.82x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
n/a
average equity is zero or negative
Return on assets
-69.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-56.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$467.4M
market value at close 2026-10-27 on 2026-08-07 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-9.0%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$44.5M$57.6M$50.6M$47.7M
Operating income-$71.1M-$30.8M-$15.1M-$42.1M
Net income-$83.8M-$44.1M-$7.9M-$54.4M
EPS (diluted)-0.78-0.51-0.13-1.12
Operating cash flow-$52.4M-$35.8M-$6.4M-$9.8M
Cash$121.2M$71.5M$23.9M$27.3M
Long-term debt$45.0M$45.0M$45.0M$33.4M
SEC XBRL, fiscal years, as known on 2026-10-28

AQST Stock Sonar score 6/7 axes

Find similar shapesCompare

AQST ranks highest on institutional and government (57th percentile) and financial health (55th), and lowest on insider conviction (21st), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
39
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-69.3% · 35 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-56.7% · 44 pct, sector of 576
Financial health
55
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.82x · 55 pct, sector of 371
Growth
30
Inputs
  • Revenue growth, YoY-22.6% · 30 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
21
Inputs
  • Net Form 4 buying (codes P and S), 180d-$472K · 41 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
57
Inputs
  • Funds adding, latest quarter93 · 65 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$230K · 48 pct, sector of 133
Risk and compliance
39
Inputs
  • Short interest, % of float+24.4% · 8 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+7.1% · 70 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

AQST filings, in plain words

Are Aquestive Therapeutics insiders buying or selling AQST?

In the 180 days to 2026-10-28, Aquestive Therapeutics insiders were net sellers, a net $744.0K across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of AQST?

Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $395.8K of stock; the latest, by Daniel Barber, was filed 2026-09-15.

Read the full summary

In the 180 days to 2026-10-28, Aquestive Therapeutics insiders were net sellers of AQST, a net $744.0K across purchases and sales reported on Form 4 by 3 sellers. 33% of the 9 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $395.8K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies